Skip to Content

Join the 'Edema' group to help and get support from people like you.

Edema Support Group


Our support group for Edema has 173 questions and 91 members. Updated 18 Sep 2017.

Popular Questions

View more questions...

Further Information

Related Condition Support Groups

Lymphatic obstruction, Fluid Retention, Fluid and Electrolye Imbalance

Related Drug Support Groups

hydrochlorothiazide, spironolactone, Lasix, furosemide, triamterene, Diamox, chlorthalidone, Aldactone, acetazolamide, view more... indapamide, Dyazide, Maxzide, bendroflumethiazide, metolazone, bumetanide, hydrochlorothiazide / triamterene, Bumex, HydroDIURIL, torsemide, Zaroxolyn, Diamox Sequels, Microzide, amiloride, Maxzide-25, Lozol, Dyrenium, pamabrom, chlorothiazide, hydrochlorothiazide / spironolactone, Aqua-Ban, Demadex, Hygroton, ethacrynic acid, Naturetin, Thalitone, Aldactazide, polythiazide, Midamor, Diuril, Edecrin, Diurese, Enduron, Saluron, Metahydrin, Naqua, Exna, Aqua-Ban with Pamabrom, Aquacot, Renese, benzthiazide, Demadex IV, Naturetin-10, Diurex Aquagels, Diurex Max, Aquatensen, Ezide, Naturetin-5, Esidrix, trichlormethiazide, methyclothiazide, hydroflumethiazide, Diaqua-2, Lo-Aqua, Diuril Sodium, Oretic, Mykrox, Hydro Par, Sodium Edecrin, Carozide, Diaqua, Loqua, Aquazide H, CaroSpir

Related Condition Guides

Search this Group

Latest News

CMP Pharma, Inc. Announces FDA Approval of CaroSpir (spironolactone) Oral Suspension

Farmville, NC. August 7, 2017 – CMP Pharma today announced that the US Food and Drug Administration (FDA) has granted final approval of the company’s New Drug Application (NDA) for CaroSpir ...

Read more news...

Latest Questions

View more questions...

Top Group Members

14,356 total answers
In this group:
22 answers
11,121 total answers
In this group:
15 answers
176 total answers
In this group:
22 answers
Rajive G...
6,060 total answers
In this group:
14 answers
3,801 total answers
In this group:
3 answers
1,080 total answers
In this group:
2 answers

View all 91 members...

Ask a Question